Fermenta Biotech FY26 Annual Report: Revenue hits record Rs 548 crore

Revenue Growth 20pctEbitda Margin ExpansionExceptional ItemResults View source PDF

FERMENTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-5.1%1-day move

₹442.85

prior close

₹447.30

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-2.0-2.5-2.3—-5.1-10.0-2.4-0.7+3.9—————

Up moveDown movePending

AI summary

Fermenta Biotech filed its FY26 Annual Report ahead of the August 11 AGM. Consolidated revenue rose 14% to a record Rs 548 crore; excluding real estate, core revenue grew 26%. Core EBITDA jumped 44% to Rs 120 crore. Reported PAT was Rs 70 crore versus Rs 76 crore in FY25, with underlying PAT stronger after stripping real-estate one-offs. Operating cash flow more than doubled to Rs 93 crore and free cash flow tripled to Rs 62 crore. Debt-to-equity eased to 0.27.

Likely market impact

Record topline and doubled cash flow signal operating momentum. New patent and Rs 110 crore capex position company for plant-source Vitamin D3 leadership.